Projects

Head of Department
doc. RNDr. Oľga Pecháňová, DrSc.

International

Finished
  • Magnesium Nanocomposites for Biodegradable Medical Implants
    Program: Inter-academic agreement
    Duration: 1. 11. 2014 – 31. 10. 2017
  • EU-ROS: The European Network on Oxidative Stress and Redox Biology Research
    Program: COST
    Duration: 1. 6. 2013 – 31. 5. 2016
  • Effects of antioxidants on metabolic syndrome: reactive oxygen species/nitric oxide balance
    Program: Inter-institute agreement
    Duration: 1. 1. 2007 – 31. 12. 2015
  • Gasotransmitters: from basic science to therapeutic applications
    Program: COST
    Duration: 1. 5. 2011 – 1. 5. 2015
  • Metabolic syndrome: inflammation in hypertension and effect of polyphenols
    Program: Inter-institute agreement
    Duration: 15. 6. 2010 – 31. 12. 2013
  • Effect of renin and (pro)renin receptor inhibition on cardiovascular system with special focus on gasotransmitters
    Program: Bilateral - other
    Duration: 1. 3. 2012 – 31. 12. 2013
  • Effect of natural polyphenols on the development and maintenance of experimental hypertension and remodelling of cardiovascular system
    Program: Inter-institute agreement
    Duration: 1. 10. 2004 – 30. 9. 2013
  • Promoting Healthy Work for Employees with Chronic Illness - Public Health and Work
    Program: Multilateral - other
    Duration: 1. 9. 2011 – 31. 8. 2013
  • Co-operation in postgraduate education
    Program: Inter-institute agreement
    Duration: 1. 1. 2008 – 31. 12. 2010
  • The effect of natural polyphenols on the damage of cardiovascular system and kidney indiced by long-term cyclosporine A treatment
    Program: Inter-institute agreement
    Duration: 1. 1. 2007 – 31. 12. 2010
  • Different models of experimental hypertension and their vasoactive systems
    Program: Inter-institute agreement
    Duration: 1. 1. 2005 – 31. 12. 2009
  • The effect of polyphenolic compounds on the prevention and regression of a tissue damage ba long-term cyclosporine A treatment
    Program: Inter-institute agreement
    Duration: 1. 1. 2004 – 31. 12. 2006

National

Current
  • Cardiovascular protection mediated by alpha 1 AMPK against metabolic syndrome-mediated endothelial dysfunction - identifying new risk factors
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • -
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • -
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
Finished
  • The effect of aging and hypertension on experimental myocardial infarction
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Centre for biomedical research - BIOMEDIRES - II. stage
    Program: EU Structural Funds Research & Development
    Duration: 12. 3. 2020 – 30. 6. 2023
  • Development of biomodels to improve efficiency assessment of drugs and substances that have the potential to treat COVID-19 (BIOVID-19)
    Program:
    Duration: 9. 6. 2021 – 30. 6. 2023
  • -
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • -
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • The effect of STAT1 and ISG15 inhibitors on biochemical and morphological parameters in experimental myocardial infarction
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2019
  • Effects of nanoencapsulated simvastatin on cardiovascular system in experimental metabolic syndrome
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • Protection of hypertensive and failure heart by I(f) channel blocker ivabradin: comparison with ACE inhibition and melatonin
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Protective effect of NO and CO donors in experimental myocardial infarction with hypertensive complications
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Cardiovascular Effects of Nanoencapsulated Simvastain and Coenzyme Q10 in Experimental Hyperlipidemia (KANASTA)
    Program: Other projects
    Duration: 27. 11. 2015 – 26. 11. 2018
  • Participation of HMGB1 in experimental myocardial infarction: cardioprotection vs. cardiac depression
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • The effect of the lifestyle-related risk factors on the adaptive processes in the ischemic myocardium
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • The effect of lifestyle-related factors on the adaptive processes in ischemic myokardium
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Centre of excellence for examination of regulatory role of nitric oxide in civilization diseases
    Program:
    Duration: 1. 8. 2011 – 30. 6. 2015
  • New model of experimental hypertension, left ventricular remodeling and heart failure induced by nuclear factor kappaB inhibition: pprotection by melatonin and captopril
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2014
  • Effect of (pro)renin antagonist (RER-24) loaded naoparticles in experimental hypertension
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2014
  • The effect of aliskiren loaded nanoparticles in experimental hypertension
    Program: SRDA
    Duration: 1. 5. 2011 – 31. 10. 2014
  • The role of nuclear factor kappa B in experimental hypertension
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2013
  • Centre of Excellence for Research and Development of Constructive Composite Materials II
    Program: EU Structural Funds Research & Development
    Duration: 1. 9. 2009 – 30. 6. 2013
  • Metabogenic factors of hypertension development: antioxidant therapy in the prevention and treatment
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Gasotransmitters: from basic science to therapeutic applications
    Program: Other projects
    Duration: 1. 5. 2011 – 1. 12. 2011
  • Centre of Excellence for Research and Development of Constructive Composite Materials I
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2009 – 28. 2. 2011
  • Centre of Excellence for Cardiovascular Research
    Program:
    Duration: 1. 1. 2007 – 31. 12. 2010
  • Hypertension and diabetes as the parts of metabolic syndrome: the effects of antioxidant therapy
    Program: SRDA
    Duration: 1. 6. 2008 – 31. 12. 2010
  • Inhibitors of HMG-CoA reductase and their alternative effects: the role of mitochondrials and coenzyme Q
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2010
  • Modification of hypertrophy and heart failure in the model of continual light-induced hypertension in rats by melatonin and captopril
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2010
  • Epigenetic risk factors of cereberal stroke
    Program: SRDA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Move Europe
    Program:
    Duration: 1. 1. 2009 – 31. 12. 2009
  • Mechanism of indapamide effect on the prevention and treatment of experimental hypertension and organ damage
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Melatonine-induced modification of hypertrophy and heart failure in NO deficient hypertension
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • The study of damaged bioenergetic and antioxidant systems in different diseases: pharmacologic and non-pharmacologic approaches in the therapy
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Role of bioflavonoids in prevention of social stress-induced hypertension
    Program: SRDA
    Duration: 1. 1. 2005 – 31. 12. 2007
Employees